查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1722667

2025 年至 2033 年阿霉素市场应用、配销通路和地区报告

Doxorubicin Market Report by Application, Distribution Channel, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 142 Pages | 商品交期: 2-3个工作天内

价格

2024 年全球阿霉素市场规模达 13.3 亿美元。展望未来， IMARC Group预计到 2033 年市场规模将达到 21.3 亿美元，2025-2033 年期间的成长率 (CAGR) 为 5.06%。

阿霉素（DOX）是一种用于治疗癌症化疗过程中的通用药物。它以注射液或冷冻干燥粉末形式经由週边插入中心静脉导管（PICC）或中心静脉导管（CVC）进行静脉给药。静脉注射后，DOX 被酵素迅速消除并在血浆中发生水解降解。它用于治疗多种类型的癌症，包括乳腺癌、膀胱癌、卡波西氏肉瘤、淋巴瘤、威尔姆斯肿瘤、非何杰金氏淋巴瘤和急性淋巴细胞白血病。

阿霉素市场趋势：

癌症发生率的上升是推动全球阿霉素市场发展的主要因素。这导致 DOX 与其他化疗药物合併使用来治疗各种癌症的情况越来越多。除此之外，对微创（MI）手术的需求不断增长以及无法接受重大手术的老年人口不断增加，导致人们越来越倾向于使用 DOX 作为癌症治疗疗法的一部分。各国政府也在实施倡议，支持临床肿瘤学的技术进步，包括静脉注射免费治疗和用于片上生化分析的数位微流体技术。他们也正在加强对癌症治疗的宣传计画。因此，对 DOX 的需求大幅增加。此外，研究人员还在临床试验上投入了大量资金，以开发技术先进的 DOX 配方。此外，预计未来几年将越来越多的併购以及针对 DOX 先进形式的临床试验的合作将为市场带来积极的前景。

本报告回答的关键问题

  • 阿霉素市场有多大？阿霉素市场未来前景如何？
  • 推动阿霉素市场发展的关键因素有哪些？
  • 哪个地区占据阿霉素最大的市占率？
  • 全球阿霉素市场领先的公司有哪些？

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

  • 概述
  • 主要行业趋势

第五章：全球阿霉素市场

  • 市场概览
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依应用

  • 乳癌
  • 卵巢癌
  • 多发骨髓瘤
  • 卡波西氏肉瘤
  • 白血病
  • 骨肉瘤
  • 子宫内膜癌
  • 其他的

第七章：市场区隔：按配销通路

  • 医院和零售药局
  • 网上商店
  • 其他的

第八章：市场区隔：依地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场区隔：依国家

第九章：SWOT分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 10 章：价值链分析

第 11 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 12 章：价格分析

第 13 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Accord Healthcare Ltd. (Intas Pharmaceuticals Limited)
    • Baxter International Inc.
    • Cadila Pharmaceuticals
    • Cipla Inc.
    • Hikma Pharmaceuticals PLC
    • Meiji Holdings Co. Ltd.
    • Novartis AG
    • Pfizer Inc.
Product Code: SR112025A5677

The global doxorubicin market size reached USD 1.33 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 2.13 Billion by 2033, exhibiting a growth rate (CAGR) of 5.06% during 2025-2033.

Doxorubicin (DOX) is a generic medicine used in the process of chemotherapy for treating cancer. It is used as an injection solution or in lyophilized powder form to intravenously administer through peripherally inserted central line catheter (PICC) or central venous catheter (CVC). DOX is rapidly eliminated by enzymes and encounters hydrolytic degradation in plasma after intravenous administration. It is used to treat several types of cancer, including breast cancer, bladder cancer, Kaposi's sarcoma, lymphoma, Wilms' tumor, non-Hodgkin's lymphoma, and acute lymphocytic leukemia.

Doxorubicin Market Trends:

The increasing prevalence of cancer is primarily driving the global doxorubicin market. This has resulted in the growing use of DOX in combination with other chemotherapeutic agents to treat a variety of carcinomas. Besides this, the rising demand for minimally invasive (MI) surgical procedures and the growing geriatric population who cannot undergo significant surgeries have led to the growing preference for DOX as part of the cancer treatment therapies. Governments of different countries are also implementing initiatives to support technological advancements in clinical oncology, including intravenous free therapy and digital microfluidics for on-chip biochemical analysis. They are also increasing awareness programs for the treatment of cancer. As a result, there has been a significant increase in the demand for DOX. Furthermore, researchers are spending a considerable amount on clinical trials to develop technologically advanced DOX formulations. Moreover, the growing number of mergers and acquisitions as well as partnerships for clinical trials with advanced forms of DOX is expected to create a positive outlook for the market in the coming years.

Key Market Segmentation:

Breakup by Application:

  • Breast Cancer
  • Ovarian Cancer
  • Multiple Myeloma
  • Kaposi Sarcoma
  • Leukemia
  • Bone Sarcoma
  • Endometrial Cancer
  • Others

Breakup by Distribution Channel:

  • Hospital and Retail Pharmacies
  • Online Stores
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Accord Healthcare Ltd. (Intas Pharmaceuticals Limited), Baxter International Inc., Cadila Pharmaceuticals, Cipla Inc., Hikma Pharmaceuticals PLC, Meiji Holdings Co. Ltd., Novartis AG and Pfizer Inc.

Key Questions Answered in This Report

  • 1.How big is the doxorubicin market?
  • 2.What is the future outlook of doxorubicin market?
  • 3.What are the key factors driving the doxorubicin market?
  • 4.Which region accounts for the largest doxorubicin market share?
  • 5.Which are the leading companies in the global doxorubicin market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Doxorubicin Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Application

  • 6.1 Breast Cancer
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Ovarian Cancer
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Multiple Myeloma
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Kaposi Sarcoma
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Leukemia
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Bone Sarcoma
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Endometrial Cancer
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast
  • 6.8 Others
    • 6.8.1 Market Trends
    • 6.8.2 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Hospital and Retail Pharmacies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Online Stores
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Accord Healthcare Ltd. (Intas Pharmaceuticals Limited)
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
    • 13.3.2 Baxter International Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Cadila Pharmaceuticals
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
    • 13.3.4 Cipla Inc.
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Hikma Pharmaceuticals PLC
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
    • 13.3.6 Meiji Holdings Co. Ltd.
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Novartis AG
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Pfizer Inc.
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Doxorubicin Market: Major Drivers and Challenges
  • Figure 2: Global: Doxorubicin Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Doxorubicin Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Doxorubicin Market: Breakup by Application (in %), 2024
  • Figure 5: Global: Doxorubicin Market: Breakup by Distribution Channel (in %), 2024
  • Figure 6: Global: Doxorubicin Market: Breakup by Region (in %), 2024
  • Figure 7: Global: Doxorubicin (Breast Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 8: Global: Doxorubicin (Breast Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 9: Global: Doxorubicin (Ovarian Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Doxorubicin (Ovarian Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Doxorubicin (Multiple Myeloma) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Doxorubicin (Multiple Myeloma) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Doxorubicin (Kaposi Sarcoma) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Doxorubicin (Kaposi Sarcoma) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Doxorubicin (Leukemia) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Doxorubicin (Leukemia) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Doxorubicin (Bone Sarcoma) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Doxorubicin (Bone Sarcoma) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Doxorubicin (Endometrial Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Doxorubicin (Endometrial Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Doxorubicin (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Doxorubicin (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Doxorubicin (Hospital and Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Doxorubicin (Hospital and Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Doxorubicin (Online Stores) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Doxorubicin (Online Stores) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Doxorubicin (Other Distribution Channels) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Doxorubicin (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: North America: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: North America: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: United States: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: United States: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Canada: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Canada: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Asia-Pacific: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Asia-Pacific: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: China: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: China: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Japan: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Japan: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: India: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: India: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: South Korea: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: South Korea: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Australia: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Australia: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Indonesia: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Indonesia: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Others: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Others: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Europe: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Europe: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Germany: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Germany: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: France: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: France: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: United Kingdom: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: United Kingdom: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Italy: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Italy: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Spain: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Spain: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Russia: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Russia: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Others: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Others: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Latin America: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Latin America: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Brazil: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Brazil: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Mexico: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Mexico: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Others: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Others: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Middle East and Africa: Doxorubicin Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Middle East and Africa: Doxorubicin Market: Breakup by Country (in %), 2024
  • Figure 77: Middle East and Africa: Doxorubicin Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Global: Doxorubicin Industry: SWOT Analysis
  • Figure 79: Global: Doxorubicin Industry: Value Chain Analysis
  • Figure 80: Global: Doxorubicin Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Doxorubicin Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Doxorubicin Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 3: Global: Doxorubicin Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 4: Global: Doxorubicin Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 5: Global: Doxorubicin Market: Competitive Structure
  • Table 6: Global: Doxorubicin Market: Key Players